



Docket No. 242791US0CONT/phh

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF: Tetsuya SUGA, et al.

SERIAL NO: 10/692,684

GAU: 1616

FILED: October 27, 2003

EXAMINER:

FOR: IMMUNE ACTIVATOR

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

COMMISSIONER FOR PATENTS
ALEXANDRIA, VIRGINIA 22313

SIR:

Applicant(s) wish to disclose the following information.

REFERENCES

- ☒ The applicant(s) wish to make of record the references cited in the attached two Japanese Office Actions listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- ☐ Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION


- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- ☐ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

- ☒ Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND,
MAIER & NEUSTADT, P.C.
Norman F. Oblon




Vincent K. Shier, Ph.D.

Registration No. 50,552

Customer Number

22850

Tel. (703) 413-3000
Fax. (703) 413-2220
(OSMMN 05/03)



Form PTO 1449 (Modified)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY DOCKET NO. 242791US0CONT		SERIAL NO. 10/692,684	
LIST OF REFERENCES CITED BY APPLICANT				APPLICANT Tetsuya SUGA, et al.			
				FILING DATE October 27, 2003		GROUP 1616	
U.S. PATENT DOCUMENTS							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						
	AM						
	AN						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO		
	AO	WO 99/61480	12/02/1999	WIPO			
	AP						
	AQ						
	AR						
	AS						
	AT						
	AU						
	AV						
OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, etc.)							
	AW	A. KASUGA, et al., Nippon Shokuhin Kogyo Gakkaishi, vol. 40, no. 1, pages 56-63, "ANTIOXIDATIVE ACTIVITIES OF SEVERAL MUSHROOM EXTRACTS", 1993 {(with English Abstract), (pages 62 and 63 will be filed later)}					
	AX	G. ABEL, et al., Int. J. Immunopharmac., vol. 11, no. 6, pages 615-621, "EFFECT OF LENTINAN AND MANNAN ON PHAGOCYTOSIS OF FLUORESCENT LATEX MICROBEADS BY MOUSE PERITONEAL MACROPHAGES: A FLOW CYTOMETRIC STUDY", 1989					
	AY	M. KUSAMA, et al., BIOTHERAPY, vol. 7, no. 5, pages 764-766, "ANALYSIS OF IMMUNOLOGICAL RESPONSE WITH LOCALLY ADMINISTRATION OF ACTIVE CHARCOAL-ABSORBED LENTINAN", April 1993 (with English summary)					
	AZ					<input type="checkbox"/> Additional References sheet(s) attached	
Examiner					Date Considered		
*Examiner: Initial if reference is considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							